The chart above explains what I mean. Keryx shares (the blue line) are down almost 13% since the start of February while the Nasdaq Biotechnology Index (NBI in orange) is up more than 23%.
I used the beginning of February as the meaningful starting point to track Keryx's performance on purpose to exclude the upward spike in the stock's value on Jan. 28. That's the day Keryx released positive results from the long-term, phase III study of its kidney dialysis phosphate binder Zerenex. Over four trading days starting Jan. 28 through Jan. 31, Keryx's stock almost tripled in value -- a reaction biotech investors are accustomed to seeing on positive clinical trial results.Since that four-day burst of buying activity, the value of Keryx shares is down 13%. Odd, particularly in the raging biotech bull market where even low-quality stocks are moving higher. Keryx is still up more than 200% year to date, so I don't mean to suggest the stock is a total laggard. Just noting that after the initial buying surge in late January caused by the Zerenex data, investors have been avoiding the stock. Why? A lot of factors might be working against Keryx but my best guess is investors lack confidence in the patent protection and market exclusivity for Zerenex. If Keryx has trouble defending its Zerenex patents and/or fails to obtain five years of market exclusivity as a New Chemical Entity (NCE) from the FDA, a Big Pharma partner or acquirer isn't likely to materialize. Investors aren't thrilled with the idea of Keryx selling Zerenex on its own, hence the stock's underperformance for most of this year. In short, Keryx equals Amarin (AMRN). I'm not going to replay the bull-bear argument over Zerenex's patents and NCE status here. Keryx and its supporters believe the Zerenex patents are enforceable and Big Pharma interest in the new phosphate binder will be significant. Investors shorting Keryx believe otherwise. Judging by the stock's performance this year, I'd say Keryx has more work to do clearing up worries about Zerenex's patents and potential for market exclusivity. One more chart to look at. This one (on the next page) tracks the performance of Acadia Pharmaceuticals (ACAD - Get Report) since the end of November 2012, after the release of positive results from the phase III study of pimavanserin in Parkinson's psychosis.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts